COMPOUNDS AND THERAPEUTIC USES THEREOF
The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders.
1 . A compound having a structure according to Formula I
and pharmaceutically acceptable salts and solvates thereof;
wherein:
Y is phenyl, 2-pyridinyl, 3-pyridinyl, or 4-pyridinyl, wherein any ring carbon is optionally independently substituted with halo, C 1-5 alkyl, nitro, cyano, C 1-5 alkoxy, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamide, amino, hydroxyl, mercapto, alkylthio, sulfonyl, or sulfinyl;
Y 1 is divalent carbocycle, divalent heterocycle, divalent phenyl or divalent heteroaryl, wherein any ring atom is optionally independently substituted with halo, C 1-5 alkyl, nitro, cyano, trihalomethyl, C 1-5 alkoxy, C-amido, N-amido, sulfonamide, amino, aminosulfonyl, hydroxyl, mercapto, alkylthio, sulfonyl, or sulfinyl, or
Y 1 is C 2-8 alkylene or C 2-8 alkenylene, optionally interrupted one, two, or three times by —O—, —S—, —S(═O)—, —S(═O) 2 —, —OC(═O)N(R)—, —N(R)C(═O)O—, —C(═O)N(R)—, —N(R)C(═O)—, —N(R)C(═O)N(R)—, —N(R)—, —C(═O)—, —OC(═O)—, —C(═O)O—, —OS(═O) 2 N(R)—, —N(R)S(═O) 2 O—, —SC(═O)—, —C(═O)S—, —OC(═S)N(R)—, —N(R)C(═S)O—, —C(═S)N(R)—, —N(R)C(═S)—, —N(R)C(═S)N(R)—, —C(═S)—, —OC(═S)—, —C(═S)O—, —S(═O) 2 N(R)—, —N(R)S(═O) 2 —, —S(═O) 2 N(R)C(═O)—, or —C(═O)N(R)S(═O) 2 —;
Y 2 is —OCH 2 —, —SCH 2 —, —N(R)CH 2 —, —N(R)C(═O)—, —C(═O)N(R)—, —S(═O) 2 CH 2 —, —S(═O)CH 2 —, —CH 2 O—, —CH 2 CH 2 O—, —CH 2 S—, —CH 2 N(R)—, —CH 2 S(═O) 2 —, —CH 2 S(═O)—, —C(═O)O—, —C(═O)—, —SO 2 N(R)—, —N(R)SO 2 —, ethylene, propylene, n-butylene, —O—C 1-4 alkylene-N(R)C(═O)-, —O—C 1-4 alkylene-C(═O)N(R)—, —N(R)C(═O)—C 1-4 alkylene-O—, —C(═O)N(R)—C 1-4 alkylene-O—, —C 1-4 alkylene-S(═O) 2 —, —C 1-4 alkylene-S(═O)—, —S(═O) 2 —C 1-4 alkylene-, —S(═O)—C 1-4 alkylene-, —C 1-4 alkylene-SO 2 N(R)—, —C 1-4 alkylene-N(R)SO 2 —, —SO 2 N(R)—C 1-4 alkylene-, —N(R)SO 2 —C 1-4 alkylene-, —C 1-4 alkylene-O—C 1-4 alkylene-, —O—C 1-4 alkylene-, —C 1-4 alkylene-O—, —S—C 1-4 alkylene-, —C 1-4 alkylene-S—, —C 1-4 alkylene-S—C 1-4 alkylene-, —N(R)—C 1-4 alkylene-, —C 1-4 alkylene-N(R)—, —C 1-4 alkylene-N(R)—C 1-4 alkylene-, —C 1-4 alkylene-C(═O)—O—C 1-4 alkylene-, —C 1-4 alkylene-O—C(═O)—C 1-4 alkylene-, —C 1-4 alkylene-C(═O)—N(R)—C 1-4 alkylene-, —C 1-4 alkylene-N(R)—C(═O)—C 1-4 alkylene-, —C(═O)—N(R)—C 1-4 alkylene-SO 2 N(R)—, or —N(R)—C(═O)—C 1-4 alkylene-SO 2 N(R)—;
Z 0 is carbocycle, cycloalkyl, cycloalkenyl, heterocycle, heterocyclonoyl, aryl, heteroaryl, carbocycloalkyl, heterocyclylalkyl, arylalkyl, arylalkenyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, or arylalkynyl, wherein any of the foregoing groups are optionally substituted at least once with alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, carbocycle, cycloalkyl, cycloalkenyl, heterocycle, aryl, heteroaryl, halo, hydro, hydroxyl, alkoxy, alkynyloxy, cycloalkyloxy, heterocycloxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, mercapto, alkylthio, arylthio, arylalkyl, heteroarylalkyl, heteroarylalkenyl, arylalkynyl, haloalkyl, aldehyde, thiocarbonyl, heterocyclonoyl, O-carboxy, C-carboxy, carboxylic acid, ester, C-carboxy salt, carboxyalkyl, carboxyalkenylene, carboxyalkyl salt, carboxyalkoxy, carboxyalkoxyalkanoyl, amino, aminoalkyl, nitro, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, aminothiocarbonyl, hydroxyaminocarbonyl, alkoxyaminocarbonyl, cyano, nitrile, cyanato, isocyanato, thiocyanato, isothiocyanato, sulfinyl, sulfonyl, sulfonamide, aminosulfonyl, aminosulfonyloxy, sulfonamidecarbonyl, alkanoylaminosulfonyl, trihalomethylsulfonyl, or trihalomethylsulfonamide;
wherein any alkylene or alkenylene group is optionally independently substituted with C 1-4 alkyl, halo, C 1-4 haloalkyl, or C 3 or C 4 cycloalkyl;
wherein for the purpose of Y 1 , R is H, halo, C 1-4 alkyl, C 1-4 alkenyl, or C 1-4 alkynyl;
wherein for the purpose of Y 2 , R is H, halo, C 1-5 alkyl, C 1-5 alkenyl, C 1-5 alkynyl, or is methylene or ethylene that forms a 5- or 6-membered heterocycle with a carbon atom of Z 0 ; and
with the proviso that the compound is NOT:
ethyl 3-(pyridin-3-yl)-4-({4-[(3-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzyl)oxy]phenyl}sulfonyl)butanoate;
4-({4-[(3-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzyl)oxy]phenyl}sulfonyl)-3-[4-(trifluoromethyl)phenyl]butanoic acid;
3-phenyl-4-({4-[(3-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzyl)oxy]phenyl}sulfonyl)butanoic acid;
3-(4-chloro-3-fluorophenyl)-4-[(4-{[3-{[(pyridin-3-ylmethyl)carbamoyl]amino}-5-(trifluoromethyl)benzyl]oxy}phenyl)sulfonyl]butanoic acid;
3-phenyl-4-[(4-{[3-{[(pyridin-3-ylmethyl)carbamoyl]amino}-5-(trifluoromethyl)benzyl]oxy}phenyl)sulfonyl]butanoic acid;
3-(pyridin-3-yl)-4-({4-[(3-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzyl)oxy]phenyl}sulfonyl)butanoic acid;
4-({4-[(4-fluoro-3-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzyl)oxy]phenyl}sulfonyl)-3-(pyridin-3-yl)butanoic acid;
1,1′-butane-1,4-diylbis[3-(pyridin-3-ylmethyl)urea];
1-[(6-methoxypyridin-3-yl)methyl]-3-[3-(3-methylphenoxy)propyl]urea; or
1-[3-(2-fluorophenoxy)propyl]-3-[(6-methoxypyridin-3-yl)methyl]urea.
2 - 10 . (canceled)
11 . A compound having a structure according to Formula II
and pharmaceutically acceptable salts and solvates thereof;
wherein:
Z is hydro, halo, C 1-5 alkyl, nitro, cyano, C 1-5 alkoxy, C-amido, N-amido, trihalomethyl, C-carboxy, O-carboxy, trihalomethyl, C-carboxy, O-carboxy, sulfonamide, amino, hydroxyl, mercapto, alkylthio, sulfonyl, or sulfinyl, wherein C 1-5 alkyl, C 1-5 alkoxy, C-amido, N-amido, amino, and alkylthio are each optionally substituted with heteroaryl, heterocyclo, cycloalkyl, alkoxy, or aminoheteroaryl, heterocyclo, cycloalkyl, alkoxy, or amino; or
Z is carbocycle, cycloalkyl, cycloalkenyl, heterocycle, heterocyclonoyl, aryl, heteroaryl, carbocycloalkyl, heterocyclylalkyl, arylalkyl, arylalkenyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, or arylalkynyl, wherein any of the foregoing groups are optionally substituted at least once with alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, carbocycle, cycloalkyl, cycloalkenyl, heterocycle, aryl, heteroaryl, halo, hydro, hydroxyl, alkoxy, alkynyloxy, cycloalkyloxy, heterocycloxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, mercapto, alkylthio, arylthio, arylalkyl, heteroarylalkyl, heteroarylalkenyl, arylalkynyl, haloalkyl, aldehyde, thiocarbonyl, heterocyclonoyl, O-carboxy, C-carboxy, carboxylic acid, ester, C-carboxy salt, carboxyalkyl, carboxyalkenylene, carboxyalkyl salt, carboxyalkoxy, carboxyalkoxyalkanoyl, amino, aminoalkyl, nitro, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, aminothiocarbonyl, hydroxyaminocarbonyl, alkoxyaminocarbonyl, cyano, nitrile, cyanato, isocyanato, thiocyanato, isothiocyanato, sulfinyl, sulfonyl, sulfonamide, aminosulfonyl, aminosulfonyloxy, sulfonamidecarbonyl, alkanoylaminosulfonyl, trihalomethylsulfonyl, or trihalomethylsulfonamide;
Y is phenyl, 2-pyridinyl, 3-pyridinyl, or 4-pyridinyl, wherein any ring carbon is optionally independently substituted with halo, C 1-5 alkyl, nitro, cyano, C 1-5 alkoxy, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamide, amino, hydroxyl, mercapto, alkylthio, sulfonyl, or sulfinyl;
Y 1 is divalent carbocycle, divalent heterocycle, divalent phenyl or divalent heteroaryl, wherein any ring atom is optionally independently substituted with halo, C 1-5 alkyl, nitro, cyano, trihalomethyl, C 1-5 alkoxy, C-amido, N-amido, sulfonamide, amino, aminosulfonyl, hydroxyl, mercapto, alkylthio, sulfonyl, or sulfinyl, or
Y 1 is C 2-8 alkylene or C 2-8 alkenylene, optionally interrupted one, two, or three times by —O—, —S—, —S(═O)—, —S(═O) 2 —, —OC(═O)N(R)—, —N(R)C(═O)O—, —C(═O)N(R)—, —N(R)C(═O)—, —N(R)C(═O)N(R)—, —N(R)—, —C(═O)—, —OC(═O)—, —C(═O)O—, —OS(═O) 2 N(R)—, —N(R)S(═O) 2 O—, —SC(═O)—, —C(═O)S—, —OC(═S)N(R)—, —N(R)C(═S)O—, —C(═S)N(R)—, —N(R)C(═S)—, —N(R)C(═S)N(R)—, —C(═S)—, —OC(═S)—, —C(═S)O—, —S(═O) 2 N(R)—, —N(R)S(═O) 2 —, —S(═O) 2 N(R)C(═O)—, or —C(═O)N(R)S(═O) 2 —;
Y 2 is —OCH 2 —, —SCH 2 —, —N(R)CH 2 —, —N(R)C(═O)—, —C(═O)N(R)—, —S(═O) 2 CH 2 —, —S(═O)CH 2 —, —CH 2 O—, —CH 2 CH 2 O—, —CH 2 S—, —CH 2 N(R)—, —CH 2 S(═O) 2 —, —CH 2 S(═O)—, —C(═O)O—, —OC(═O)—, —SO 2 N(R)—, —N(R)SO 2 —, ethylene, propylene, n-butylene, —O—C 1-4 alkylene-N(R)C(═O)-, —O—C 1-4 alkylene-C(═O)N(R)—, —N(R)C(═O)—C 1-4 alkylene-O—, —C(═O)N(R)—C 1-4 alkylene-O—, —C 1-4 alkylene-S(═O) 2 —, —C 1-4 alkylene-S(═O)—, —S(═O) 2 —C 1-4 alkylene-, —S(═O)—C 1-4 alkylene-, —C 1-4 alkylene-SO 2 N(R)—, —C 1-4 alkylene-N(R)SO 2 —, —SO 2 N(R)—C 1-4 alkylene-, —N(R)SO 2 —C 1-4 alkylene-, —C 1-4 alkylene-O—C 1-4 alkylene-, —O—C 1-4 alkylene-, —C 1-4 alkylene-O—, —S—C 1-4 alkylene-, —C 1-4 alkylene-S—, —C 1-4 alkylene-S—C 1-4 alkylene-, —N(R)—C 1-4 alkylene-, —C 1-4 alkylene-N(R)—, —C 1-4 alkylene-N(R)—C 1-4 alkylene-, —C 1-4 alkylene-C(═O)—O—C 1-4 alkylene-, —C 1-4 alkylene-O—C(═O)—C 1-4 alkylene-, —C 1-4 alkylene-C(═O)—N(R)—C 1-4 alkylene-, —C 1-4 alkylene-N(R)—C(═O)—C 1-4 alkylene-, —C(═O)—N(R)—C 1-4 alkylene-SO 2 N(R)—, or —N(R)—C(═O)—C 1-4 alkylene-SO 2 N(R)—;
wherein for the purpose of Y 1 , R is H, halo, C 1-4 alkyl, C 1-4 alkenyl, or C 1-4 alkynyl;
wherein for the purpose of Y 2 , R is H, C 1-5 alkyl, C 1-5 alkenyl, C 1-5 alkynyl, or is methylene or ethylene that forms a 5- or 6-membered heterocycle with a carbon atom of Y 3 ;
Y 3 is aryl or heteroaryl, wherein any ring carbon is optionally independently substituted with halo, C 1-5 alkyl, nitro, cyano, trihalomethyl, C 1-5 alkoxy, C-amido, N-amido, sulfonamide, amino, aminosulfonyl, hydroxyl, mercapto, alkylthio, sulfonyl, or sulfinyl, wherein C 1-5 alkyl, C 1-5 alkoxy, C-amido, N-amido, amino, and alkylthio are each optionally substituted with heteroaryl, heterocyclo, cycloalkyl, alkoxy, or aminoheteroaryl, heterocyclo, cycloalkyl, alkoxy, or amino;
any alkylene or alkenylene group is optionally independently substituted with C 1-4 alkyl, halo, C 1-4 haloalkyl, or C 3 or C 4 cycloalkyl; and
with the proviso that the compound is NOT:
1-[(6-methoxypyridin-3-yl)methyl]-3-[3-(3-methylphenoxy)propyl]urea;
1-[3-(2-fluorophenoxy)propyl]-3-[(6-methoxypyridin-3-yl)methyl]urea;
ethyl 3-(pyridin-3-yl)-4-({4-[(3-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzyl)oxy]phenyl}sulfonyl)butanoate;
4-({4-[(3-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzyl)oxy]phenyl}sulfonyl)-3-[4-(trifluoromethyl)phenyl]butanoic acid;
3-phenyl-4-({4-[(3-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzyl)oxy]phenyl}sulfonyl)butanoic acid;
3-(4-chloro-3-fluorophenyl)-4-[(4-{[3-{[(pyridin-3-ylmethyl)carbamoyl]amino}-5-(trifluoromethyl)benzyl]oxy}phenyl)sulfonyl]butanoic acid;
3-phenyl-4-[(4-{[3-{[(pyridin-3-ylmethyl)carbamoyl]amino}-5-(trifluoromethyl)benzyl]oxy}phenyl)sulfonyl]butanoic acid;
3-(pyridin-3-yl)-4-({4-[(3-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzyl)oxy]phenyl}sulfonyl)butanoic acid; or
4-({4-[(4-fluoro-3-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzyl)oxy]phenyl}sulfonyl)-3-(pyridin-3-yl)butanoic acid.
12 - 28 . (canceled)
29 . A compound having a structure according to Formula III
and pharmaceutically acceptable salts and solvates thereof;
wherein:
Y is phenyl, 2-pyridinyl, 3-pyridinyl, or 4-pyridinyl, wherein any ring carbon is optionally independently substituted with halo, C 1-5 alkyl, nitro, cyano, C 1-5 alkoxy, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamide, amino, hydroxyl, mercapto, alkylthio, sulfonyl, or sulfinyl;
Y 1 is divalent carbocycle, divalent heterocycle, divalent phenyl or divalent heteroaryl, wherein any ring atom is optionally independently substituted with halo, C 1-5 alkyl, nitro, cyano, trihalomethyl, C 1-5 alkoxy, C-amido, N-amido, sulfonamide, amino, aminosulfonyl, hydroxyl, mercapto, alkylthio, sulfonyl, or sulfinyl, or
Y 1 is C 2-8 alkylene or C 2-8 alkenylene, optionally interrupted one, two, or three times by —O—, —S—, —S(═O)—, —S(═O) 2 —, —OC(═O)N(R)—, —N(R)C(═O)O—, —C(═O)N(R)—, —N(R)C(═O)—, —N(R)C(═O)N(R)—, —N(R)—, —C(═O)—, —OC(═O)—, —C(═O)O—, —OS(═O) 2 N(R)—, —N(R)S(═O) 2 O—, —SC(═O)—, —C(═O)S—, —OC(═S)N(R)—, —N(R)C(═S)O—, —C(═S)N(R)—, —N(R)C(═S)—, —N(R)C(═S)N(R)—, —C(═S)—, —OC(═S)—, —C(═S)O—, —S(═O) 2 N(R)—, —N(R)S(═O) 2 —, —S(═O) 2 N(R)C(═O)—, or —C(═O)N(R)S(═O) 2 —;
wherein for the purpose of Y 1 , R is H, halo, C 1-4 alkyl, C 1-4 alkenyl, or C 1-4 alkynyl;
Y 2 is —OCH 2 —, —SCH 2 —, —N(R)CH 2 —, —N(R)C(═O)—, —C(═O)N(R)—, —S(═O) 2 CH 2 —, —S(═O)CH 2 —, —CH 2 O—, —CH 2 CH 2 O—, —CH 2 S—, —CH 2 N(R)—, —CH 2 S(═O) 2 —, —CH 2 S(═O)—, —C(═O)O—, —OC(═O)—, —SO 2 N(R)—, —N(R)SO 2 —, ethylene, propylene, n-butylene, —O—C 1-4 alkylene-N(R)C(═O)—, —O—C 1-4 alkylene-C(═O)N(R)—, —N(R)C(═O)—C 1-4 alkylene-O—, —C(═O)N(R)—C 1-4 alkylene-O—, —C 1-4 alkylene-S(═O) 2 —, —C 1-4 alkylene-S(═O)—, —S(═O) 2 —C 1-4 alkylene-, —S(═O)—C 1-4 alkylene-, —C 1-4 alkylene-SO 2 N(R)—, —C 1-4 alkylene-N(R)SO 2 —, —SO 2 N(R)—C 1-4 alkylene-, —N(R)SO 2 —C 1-4 alkylene-, —C 1-4 alkylene-O—C 1-4 alkylene-, —O—C 1-4 alkylene-, —C 1-4 alkylene-O—, —S—C 1-4 alkylene-, —C 1-4 alkylene-S—, —C 1-4 alkylene-S—C 1-4 alkylene-, —N(R)—C 1-4 alkylene-, —C 1-4 alkylene-N(R)—, —C 1-4 alkylene-N(R)—C 1-4 alkylene-, —C 1-4 alkylene-C(═O)—O—C 1-4 alkylene-, —C 1-4 alkylene-O—C(═O)—C 1-4 alkylene-, —C 1-4 alkylene-C(═O)—N(R)—C 1-4 alkylene-, —C 1-4 alkylene-N(R)—C(═O)—C 1-4 alkylene-, —C(═O)—N(R)—C 1-4 alkylene-SO 2 N(R)—, or —N(R)—C(═O)—C 1-4 alkylene-SO 2 N(R)—;
wherein for the purpose of Y 2 , R is H, C 1-5 alkyl, C 1-5 alkenyl, C 1-5 alkynyl, or is methylene or ethylene that forms a 5- or 6-membered heterocycle with a carbon atom of Y 3 ;
Y 3 is aryl or heteroaryl, wherein any ring carbon is optionally independently substituted with halo, C 1-5 alkyl, nitro, cyano, trihalomethyl, C 1-5 alkoxy, C-amido, N-amido, sulfonamide, amino, aminosulfonyl, hydroxyl, mercapto, alkylthio, sulfonyl, or sulfinyl, wherein C 1-5 alkyl, C 1-5 alkoxy, C-amido, N-amido, amino, and alkylthio are each optionally substituted with heteroaryl, heterocyclo, cycloalkyl, alkoxy, or aminoheteroaryl, heterocyclo, cycloalkyl, alkoxy, or amino;
Y 4 is optionally present, and when present is aryl, heteroaryl, carbocycle, or heterocycle, wherein any ring atom is optionally independently substituted with halo, C 1-5 alkyl, nitro, cyano, trihalomethyl, C 1-5 alkoxy, C-amido, N-amido, sulfonamide, amino, aminosulfonyl, hydroxyl, mercapto, alkylthio, sulfonyl, sulfinyl, wherein C 1-5 alkyl, C 1-5 alkoxy, C-amido, N-amido, amino, and alkylthio are each optionally substituted with heteroaryl, heterocyclo, cycloalkyl, alkoxy, or aminoheteroaryl, heterocyclo, cycloalkyl, alkoxy, or amino;
o, p, and q are each independently 0, 1, or 2;
any alkylene or alkenylene group of the o, p, and q regions and of Y 2 is optionally substituted with unsubstituted C 1-4 alkyl, halo, unsubstituted C 1-4 haloalkyl, or unsubstituted C 3 or C 4 cycloalkyl;
with the proviso that when p is 0, Y 1 is divalent phenyl, Y 2 is —C(═O)N(H)— or —OC(H) 2 C(═O)N(H)—, and Y 3 is phenyl or pyridinyl, then either Y 4 is present or any substituent on Y 3 is not —C(═O)NH 2 ; and
with the proviso that the compound is NOT:
1-(6-methoxy-3-pyridyl)-3-[[4-(3-pyridylmethoxy)phenyl]methyl]urea;
1-[(6-methoxypyridin-3-yl)methyl]-3-[3-(3-methylphenoxy)propyl]urea;
1-[3-(2-fluorophenoxy)propyl]-3-[(6-methoxypyridin-3-yl)methyl]urea;
ethyl 3-(pyridin-3-yl)-4-({4-[(3-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzyl)oxy]phenyl}sulfonyl)butanoate;
4-({4-[(3-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzyl)oxy]phenyl}sulfonyl)-3-[4-(trifluoromethyl)phenyl]butanoic acid;
3-phenyl-4-({4-[(3-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzyl)oxy]phenyl}sulfonyl)butanoic acid;
3-(4-chloro-3-fluorophenyl)-4-[(4-{[3-{[(pyridin-3-ylmethyl)carbamoyl]amino}-5-(trifluoromethyl)benzyl]oxy}phenyl)sulfonyl]butanoic acid;
3-phenyl-4-[(4-{[3-{[(pyridin-3-ylmethyl)carbamoyl]amino}-5-(trifluoromethyl)benzyl]oxy}phenyl)sulfonyl]butanoic acid;
3-(pyridin-3-yl)-4-({4-[(3-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzyl)oxy]phenyl}sulfonyl)butanoic acid;
4-({4-[(4-fluoro-3-{[(pyridin-3-lmethyl)carbamoyl]amino}benzyl)oxy]phenyl}sulfonyl)-3-(pyridin-3-yl)butanoic acid;
Benzoic acid, 2-hydroxy-4-[[(3-pyridinylamino)carbonyl]amino]-, phenyl ester;
Benzamide, N-(3-amino-4-pyridinyl)-4-[[[[(3-pyridinylmethyl)amino]carbonyl]amino]methyl]-;
Benzamide, N-(2-amino-3-pyridinyl)-4-[[[[(3-pyridinylmethyl)amino]carbonyl]amino]methyl]-;
Benzamide, N-(2-amino-5-fluorophenyl)-4-[[[[(3-pyridinylmethyl)amino]carbonyl]amino]methyl]-;
Benzamide, N-(2-hydroxyphenyl)-4-[[[[(3-pyridinylmethyl)amino]carbonyl]amino]methyl]-;
Benzamide, N-(2-amino-5-chlorophenyl)-4-[[[[(3-pyridinylmethyl)amino]carbonyl]amino]methyl]-;
Benzamide, 2-chloro-5-nitro-N-[4-[[(4-pyridinylamino)carbonyl]amino]phenyl]-;
Benzamide, N-[4-[[[3-(diethylamino)propyl]amino]carbonyl]phenyl]-4-[[(3-pyridinylamino)carbonyl]amino]-;
Benzamide, N-(2-aminophenyl)-4-[[[(3-pyridinylamino)carbonyl]amino]methyl]-;
Benzamide, N-(2-aminophenyl)-4-[2-[[[(3-pyridinylmethyl)amino]carbonyl]amino]ethyl]-;
Benzamide, N-(2-aminophenyl)-4-[[[[(3-pyridinylmethyl)amino]carbonyl]amino]methyl]-;
Benzoic acid, 2-hydroxy-4-[[(3-pyridinylamino)carbonyl]amino]-, phenyl ester;
1,3-Benzenedicarboxamide, N,N′-bis[3-(diethylamino)propyl]-5-[[4-[[(4-pyridinylamino) carbonyl]amino]benzoyl]amino]-;
Urea, N-[4-(phenylmethoxy)phenyl]-N′-[2-(3-pyridinyl)ethyl]-;
Urea, N-[4-(phenylmethoxy)phenyl]-N′-3-pyridinyl-;
Urea, N-(6-methyl-3-pyridinyl)-N′-[2-[2-(phenylmethoxy)phenyl]ethyl]-;
Urea, N-(6-methoxy-3-pyridinyl)-N′-[4-(phenylmethoxy)phenyl]-;
4,6-Pyrimidinedicarboxamide, N4-[[4-[[[(2,6-dichloro-4-pyridinyl)amino]carbonyl]amino]phenyl]methyl]-N-6-[(3-methoxyphenyl)methyl]-;
Benzenesulfonamide, 4-fluoro-N-[4-[[(3-pyridinylamino)carbonyl]amino]phenyl]-; or
Hexanamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[2-chloro-4-[[[(2-chloro-3-pyridinyl)amino]carbonyl]amino]-5-hydroxyphenyl]-.
30 . The compound of claim 29 , wherein the structure is according to Formula IIIa
and pharmaceutically acceptable salts and solvates thereof;
wherein:
Y is 3-pyridinyl or 4-pyridinyl, wherein any ring carbon is optionally independently substituted with halo, C 1-5 alkyl, nitro, cyano, C 1-5 alkoxy, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamide, amino, hydroxyl, mercapto, alkylthio, sulfonyl, or sulfinyl;
Y 2 , Y 3 , Y 4 , and q are as defined in claim 29 ;
n is 3, 4, 5, 6, or 7; and
any methylene group of Y 2 and the n and q regions is optionally independently substituted with C 1-4 alkyl, halo, C 1-4 haloalkyl, or C 3 or C 4 cycloalkyl.
31 - 36 . (canceled)
37 . The compound of claim 29 , wherein the structure is according to Formula IIIb
and pharmaceutically acceptable salts and solvates thereof;
wherein:
Y is 3-pyridinyl or 4-pyridinyl, wherein any ring carbon is optionally independently substituted with halo, C 1-5 alkyl, nitro, cyano, C 1-5 alkoxy, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamide, amino, hydroxyl, mercapto, alkylthio, sulfonyl, or sulfinyl;
o, p, q, Y 2 , Y 3 , and Y 4 are as defined in claim 29 ;
any methylene group of the o, p, and q regions and Y 2 is optionally independently substituted with C 1-4 alkyl, halo, C 1-4 haloalkyl, or C 3 or C 4 cycloalkyl;
R 6 , if present one or more times, is independently selected from halo, C 1-5 alkyl, nitro, cyano, C 1-5 alkoxy, C-amido, N-amido, trihalomethyl, C-carboxy, O-carboxy, sulfonamide, amino, hydroxyl, mercapto, alkylthio, sulfonyl, and sulfinyl;
wherein S, T, U, and V are carbon or nitrogen, provided that when S, T, U, or V is nitrogen, then there is no substituent on the nitrogen;
with the proviso that when p is 0, Y 2 is —C(═O)N(H)— or —OC(H) 2 C(═O)N(H)—, and Y 3 is phenyl or pyridinyl, then either Y 4 is present or any substituent on Y 3 is not —C(═O)NH 2 ; and
with the proviso that the compound is NOT
1-(6-methoxy-3-pyridyl)-3-[[4-(3-pyridylmethoxy)phenyl]methyl]urea,
ethyl 3-(pyridin-3-yl)-4-({4-[(3-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzyl)oxy]phenyl}sulfonyl)butanoate;
4-({4-[(3-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzyl)oxy]phenyl}sulfonyl)-3-[4-(trifluoromethyl)phenyl]butanoic acid;
3-phenyl-4-({4-[(3-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzyl)oxy]phenyl}sulfonyl)butanoic acid;
3-(4-chloro-3-fluorophenyl)-4-[(4-{[3-{[(pyridin-3-ylmethyl)carbamoyl]amino}-5-(trifluoromethyl)benzyl]oxy}phenyl)sulfonyl]butanoic acid;
3-phenyl-4-[(4-{[3-{[(pyridin-3-ylmethyl)carbamoyl]amino}-5-(trifluoromethyl)benzyl]oxy}phenyl)sulfonyl]butanoic acid;
3-(pyridin-3-yl)-4-({4-[(3-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzyl)oxy]phenyl}sulfonyl)butanoic acid;
4-({4-[(4-fluoro-3-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzyl)oxy]phenyl}sulfonyl)-3-(pyridin-3-yl)butanoic acid;
Benzoic acid, 2-hydroxy-4-[[(3-pyridinylamino)carbonyl]amino]-, phenyl ester,
Benzamide, N-(3-amino-4-pyridinyl)-4-[[[[(3-pyridinylmethyl)amino]carbonyl]amino]methyl]-,
Benzamide, N-(2-amino-3-pyridinyl)-4-[[[[(3-pyridinylmethyl)amino]carbonyl]amino]methyl]-,
Benzamide, N-(2-amino-5-fluorophenyl)-4-[[[[(3-pyridinylmethyl)amino]carbonyl]amino]methyl]-,
Benzamide, N-(2-hydroxyphenyl)-4-[[[[(3-pyridinylmethyl)amino]carbonyl]amino]methyl]-,
Benzamide, N-(2-amino-5-chlorophenyl)-4-[[[[(3-pyridinylmethyl)amino]carbonyl]amino]methyl]-,
Benzamide, 2-chloro-5-nitro-N-[4-[[(4-pyridinylamino)carbonyl]amino]phenyl]-,
Benzamide, N-[4-[[[3-(diethylamino)propyl]amino]carbonyl]phenyl]-4-[[(3-pyridinylamino)carbonyl]amino]-,
Benzamide, N-(2-aminophenyl)-4-[[[(3-pyridinylamino)carbonyl]amino]methyl]-,
Benzamide, N-(2-aminophenyl)-4-[2-[[[(3-pyridinylmethyl)amino]carbonyl]amino]ethyl]-,
Benzamide, N-(2-aminophenyl)-4-[[[[(3-pyridinylmethyl)amino]carbonyl]amino]methyl]-,
Benzoic acid, 2-hydroxy-4-[[(3-pyridinylamino)carbonyl]amino]-, phenyl ester,
1,3-Benzenedicarboxamide, N,N′-bis[3-(diethylamino)propyl]-5-[[4-[[(4-pyridinylamino)carbonyl]amino]benzoyl]amino]-,
Urea, N-[4-(phenylmethoxy)phenyl]-N′-[2-(3-pyridinyl)ethyl]-,
Urea, N-[4-(phenylmethoxy)phenyl]-N′-3-pyridinyl-,
Urea, N-(6-methyl-3-pyridinyl)-N′-[2-[2-(phenylmethoxy)phenyl]ethyl]-,
Urea, N-(6-methoxy-3-pyridinyl)-N′-[4-(phenylmethoxy)phenyl]-,
4,6-Pyrimidinedicarboxamide, N4-[[4-[[[(2,6-dichloro-4-pyridinyl)amino]carbonyl]amino]phenyl]methyl]-N-6-[(3-methoxyphenyl)methyl]-,
Benzenesulfonamide, 4-fluoro-N-[4-[[(3-pyridinylamino)carbonyl]amino]phenyl]-, or
Hexanamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[2-chloro-4-[[[(2-chloro-3-pyridinyl)amino]carbonyl]amino]-5-hydroxyphenyl]-.
38 . The compound of claim 37 , wherein the structure is according to Formula IIIb1
and pharmaceutically acceptable salts and solvates thereof;
wherein:
Y and R 6 are as defined in claim 37 ;
o, p, q, Y 3 , and Y 4 are as defined in claim 29 ;
any methylene group of the o, p, and q regions is optionally independently substituted with C 1-4 alkyl, halo, C 1-4 haloalkyl, or C 3 or C 4 cycloalkyl; and
R 3 and R 4 are each independently H, halo, or C 1-4 alkyl, or R 3 and R 4 , taken together with the carbon to which they are attached, form a cyclopropyl or cyclobutyl ring.
39 . The compound of claim 37 , wherein the structure is according to Formula IIIb4
and pharmaceutically acceptable salts and solvates thereof;
wherein:
Y and R 6 are as defined in claim 37 ;
o, p, q, and Y 4 are as defined in claim 29 ;
R 1 , if present one or more times, is independently selected from halo, C 1-5 alkyl, nitro, cyano, C 1-5 alkoxy, C-amido, N-amido, trihalomethyl, C-carboxy, O-carboxy, sulfonamide, amino, aminoalkyl, hydroxyl, mercapto, alkylthio, sulfonyl, and sulfinyl, wherein C 1-5 alkyl, C 1-5 alkoxy, C-amido, N-amido, amino, aminoalkyl, and alkylthio are each optionally substituted with heteroaryl, heterocyclo, cycloalkyl, alkoxy, or aminoheteroaryl, heterocyclo, cycloalkyl, alkoxy, or amino;
R 3 and R 4 are each independently H, halo, or C 1-4 alkyl, or R 3 and R 4 , taken together with the carbon to which they are attached, form a cyclopropyl or cyclobutyl ring; and
any methylene group of the o, p, and q regions is optionally independently substituted with C 1-4 alkyl, halo, C 1-4 haloalkyl, or C 3 or C 4 cycloalkyl.
40 . (canceled)
41 . The compound of claim 37 , wherein the structure is according to Formula IIIb2
and pharmaceutically acceptable salts and solvates thereof;
wherein:
Y and R 6 are as defined in claim 37 ;
o, p, q, Y 3 , and Y 4 are as defined in claim 29 ;
any methylene group of the o, p, and q regions is optionally independently substituted with C 1-4 alkyl, halo, C 1-4 haloalkyl, or C 3 or C 4 cycloalkyl; and
R 2 is H, halo, C 1-5 alkyl, C 1-5 alkenyl, or C 1-5 alkynyl.
42 . The compound of claim 37 , wherein the structure is according to Formula IIIb5
and pharmaceutically acceptable salts and solvates thereof;
wherein:
Y and R 6 are as defined in claim 37 ;
o, p, q, and Y 4 are as defined in claim 29 ;
R 1 , if present one or more times, is independently selected from halo, C 1-5 alkyl, nitro, cyano, C 1-5 alkoxy, C-amido, N-amido, trihalomethyl, C-carboxy, O-carboxy, sulfonamide, amino, aminoalkyl, hydroxyl, mercapto, alkylthio, sulfonyl, and sulfinyl, wherein C 1-5 alkyl, C 1-5 alkoxy, C-amido, N-amido, amino, aminoalkyl, and alkylthio are each optionally substituted with heteroaryl, heterocyclo, cycloalkyl, alkoxy, or aminoheteroaryl, heterocyclo, cycloalkyl, alkoxy, or amino;
R 2 is H, halo, C 1-5 alkyl, C 1-5 alkenyl, or C 1-5 alkynyl; and
any methylene group of the o, p, and q regions is optionally independently substituted with C 1-4 alkyl, halo, C 1-4 haloalkyl, or C 3 or C 4 cycloalkyl.
43 . (canceled)
44 . The compound of claim 37 , wherein the structure is according to Formula IIIb3
and pharmaceutically acceptable salts and solvates thereof;
wherein:
Y and R 6 are as defined in claim 37 ;
o, p, q, Y 3 , and Y 4 are as defined in claim 29 ;
u is 0 or 1; and
any methylene group of the o, p, q, and u regions is optionally independently substituted with C 1-4 alkyl, halo, C 1-4 haloalkyl, or C 3 or C 4 cycloalkyl.
45 . The compound of claim 37 , wherein the structure is according to Formula IIIb6
and pharmaceutically acceptable salts and solvates thereof;
wherein:
Y and R 6 are as defined in claim 37 ;
o, p, q, and Y 4 are as defined in claim 29 ;
u is 0 or 1;
R 1 , if present one or more times, is independently selected from halo, C 1-5 alkyl, nitro, cyano, C 1-5 alkoxy, C-amido, N-amido, trihalomethyl, C-carboxy, O-carboxy, sulfonamide, amino, aminoalkyl, hydroxyl, mercapto, alkylthio, sulfonyl, and sulfinyl, wherein C 1-5 alkyl, C 1-5 alkoxy, C-amido, N-amido, amino, aminoalkyl, and alkylthio are each optionally substituted with heteroaryl, heterocyclo, cycloalkyl, alkoxy, or aminoheteroaryl, heterocyclo, cycloalkyl, alkoxy, or amino; and
any methylene group of the o, p, q, and u regions is optionally independently substituted with C 1-4 alkyl, halo, C 1-4 haloalkyl, or C 3 or C 4 cycloalkyl.
46 . (canceled)
47 . The compound of claim 37 , wherein the structure is according to Formula IIIb10
and pharmaceutically acceptable salts and solvates thereof;
wherein:
Y and R 6 are as defined in claim 37 ;
o, p, and q are as defined in claim 29 ;
R 1 and R 5 , if one or both are present one or more times, are each independently selected from halo, C 1-5 alkyl, nitro, cyano, C 1-5 alkoxy, C-amido, N-amido, trihalomethyl, C-carboxy, O-carboxy, sulfonamide, amino, aminoalkyl, hydroxyl, mercapto, alkylthio, sulfonyl, and sulfinyl, wherein C 1-5 alkyl, C 1-5 alkoxy, C-amido, N-amido, amino, aminoalkyl, and alkylthio are each optionally substituted with heteroaryl, heterocyclo, cycloalkyl, alkoxy, or aminoheteroaryl, heterocyclo, cycloalkyl, alkoxy, or amino;
R 3 and R 4 are each independently H, halo, or C 1-4 alkyl, or R 3 and R 4 , taken together with the carbon to which they are attached, form a cyclopropyl or cyclobutyl ring;
R 6 is as defined for Formula IIIb above;
any methylene group of the o, p, and q regions is optionally independently substituted with C 1-4 alkyl, halo, C 1-4 haloalkyl, or C 3 or C 4 cycloalkyl; and
S, T, U, and V are carbon or nitrogen, provided that at least one of S, T, U, and V is nitrogen and that when S, T, U, or V is nitrogen, then there is no substituent on the nitrogen.
48 . The compound of claim 37 , wherein the structure is according to Formula IIIb11
and pharmaceutically acceptable salts and solvates thereof;
wherein:
Y and R 6 are as defined in claim 37 ;
o, p, and q are as defined in claim 29 ;
R 1 , if one or both are present one or more times, is independently selected from halo, C 1-5 alkyl, nitro, cyano, C 1-5 alkoxy, C-amido, N-amido, trihalomethyl, C-carboxy, O-carboxy, sulfonamide, amino, aminoalkyl, hydroxyl, mercapto, alkylthio, sulfonyl, and sulfinyl, wherein C 1-5 alkyl, C 1-5 alkoxy, C-amido, N-amido, amino, aminoalkyl, and alkylthio are each optionally substituted with heteroaryl, heterocyclo, cycloalkyl, alkoxy, or aminoheteroaryl, heterocyclo, cycloalkyl, alkoxy, or amino;
R 2 is H, halo, C 1-5 alkyl, C 1-5 alkenyl, or C 1-5 alkynyl;
any methylene group of the o, p, and q regions is optionally independently substituted with C 1-4 alkyl, halo, C 1-4 haloalkyl, or C 3 or C 4 cycloalkyl; and
S, T, U, and V are carbon or nitrogen, provided that at least one of S, T, U, and V is nitrogen and that when S, T, U, or V is nitrogen, then there is no substituent on the nitrogen.
49 . The compound of claim 37 , wherein the structure is according to Formula IIIc
and pharmaceutically acceptable salts and solvates thereof;
wherein:
Y and R 6 are as defined in claim 37 ;
Y 2 , o, p, and q are as defined in claim 29 ;
R 1 and R 5 , if one or both are present one or more times, are each independently selected from halo, C 1-5 alkyl, nitro, cyano, C 1-5 alkoxy, C-amido, N-amido, trihalomethyl, C-carboxy, O-carboxy, sulfonamide, amino, aminoalkyl, hydroxyl, mercapto, alkylthio, sulfonyl, and sulfinyl, wherein C 1-5 alkyl, C 1-5 alkoxy, C-amido, N-amido, amino, aminoalkyl, and alkylthio are each optionally substituted with heteroaryl, heterocyclo, cycloalkyl, alkoxy, or aminoheteroaryl, heterocyclo, cycloalkyl, alkoxy, or amino; and
any methylene group of the o, p, and q regions, or Y 2 , is optionally independently substituted with C 1-4 alkyl, halo, C 1-4 haloalkyl, or C 3 or C 4 cycloalkyl.
50 . A compound having a structure according to Formula IV
and pharmaceutically acceptable salts and solvates thereof;
wherein:
Y is phenyl, 2-pyridinyl, 3-pyridinyl, or 4-pyridinyl, wherein any ring carbon is optionally independently substituted with halo, C 1-5 alkyl, nitro, cyano, C 1-5 alkoxy, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamide, amino, hydroxyl, mercapto, alkylthio, sulfonyl, or sulfinyl;
Y 1 is divalent carbocycle, divalent heterocycle, divalent phenyl or divalent heteroaryl, wherein any ring atom is optionally independently substituted with halo, C 1-5 alkyl, nitro, cyano, trihalomethyl, C 1-5 alkoxy, C-amido, N-amido, sulfonamide, amino, aminosulfonyl, hydroxyl, mercapto, alkylthio, sulfonyl, or sulfinyl, or
Y 1 is C 2-8 alkylene or C 2-8 alkenylene, optionally interrupted one, two, or three times by —O—, —S—, —S(═O)—, —S(═O) 2 —, —OC(═O)N(R)—, —N(R)C(═O)O—, —C(═O)N(R)—, —N(R)C(═O)—, —N(R)C(═O)N(R)—, —N(R)—, —C(═O)—, —OC(═O)—, —C(═O)O—, —OS(═O) 2 N(R)—, —N(R)S(═O) 2 O—, —SC(═O)—, —C(═O)S—, —OC(═S)N(R)—, —N(R)C(═S)O—, —C(═S)N(R)—, —N(R)C(═S)—, —N(R)C(═S)N(R)—, —C(═S)—, —OC(═S)—, —C(═S)O—, —S(═O) 2 N(R)—, —N(R)S(═O) 2 —, —S(═O) 2 N(R)C(═O)—, or —C(═O)N(R)S(═O) 2 —;
wherein for the purpose of Y 1 , R is H, halo, C 1-4 alkyl, C 1-4 alkenyl, or C 1-4 alkynyl;
Y 2 is —OCH 2 —, —SCH 2 —, —N(R)CH 2 —, —N(R)C(═O)—, —C(═O)N(R)—, —S(═O) 2 CH 2 —, —S(═O)CH 2 —, —CH 2 O—, —CH 2 CH 2 O—, —CH 2 S—, —CH 2 N(R)—, —CH 2 S(═O) 2 —, —CH 2 S(═O)—, —C(═O)O—, —OC(═O)—, —SO 2 N(R)—, —N(R)SO 2 —, ethylene, propylene, n-butylene, —O—C 1-4 alkylene-N(R)C(═O)—, —O—C 1-4 alkylene-C(═O)N(R)—, —N(R)C(═O)—C 1-4 alkylene-O—, —C(═O)N(R)—C 1-4 alkylene-O—, —C 1-4 alkylene-S(═O) 2 —, —C 1-4 alkylene-S(═O)—, —S(═O) 2 —C 1-4 alkylene-, —S(═O)—C 1-4 alkylene-, —C 1-4 alkylene-SO 2 N(R)—, —C 1-4 alkylene-N(R)SO 2 —, —SO 2 N(R)—C 1-4 alkylene-, —N(R)SO 2 —C 1-4 alkylene-, —C 1-4 alkylene-O—C 1-4 alkylene-, —O—C 1-4 alkylene-, —C 1-4 alkylene-O—, —S—C 1-4 alkylene-, —C 1-4 alkylene-S—, —C 1-4 alkylene-S—C 1-4 alkylene-, —N(R)—C 1-4 alkylene-, —C 1-4 alkylene-N(R)—, —C 1-4 alkylene-N(R)—C 1-4 alkylene-, —C 1-4 alkylene-C(═O)—O—C 1-4 alkylene-, —C 1-4 alkylene-O—C(═O)—C 1-4 alkylene-, —C 1-4 alkylene-C(═O)—N(R)—C 1-4 alkylene-, —C 1-4 alkylene-N(R)—C(═O)—C 1-4 alkylene-, —C(═O)—N(R)—C 1-4 alkylene-SO 2 N(R)—, or —N(R)—C(═O)—C 1-4 alkylene-SO 2 N(R)—;
wherein for the purpose of Y 2 , R is H, C 1-5 alkyl, C 1-5 alkenyl, C 1-5 alkynyl, or is methylene or ethylene that forms a 5- or 6-membered heterocycle with a carbon atom of Y 3 ;
Y 3 is aryl or heteroaryl, wherein any ring carbon is optionally independently substituted with halo, C 1-5 alkyl, nitro, cyano, trihalomethyl, C 1-5 alkoxy, C-amido, N-amido, sulfonamide, amino, aminosulfonyl, hydroxyl, mercapto, alkylthio, sulfonyl, or sulfinyl, wherein C 1-5 alkyl, C 1-5 alkoxy, C-amido, N-amido, amino, and alkylthio are each optionally substituted with heteroaryl, heterocyclo, cycloalkyl, alkoxy, or amino;
Y 4 is optionally present, and when present is aryl, heteroaryl, carbocycle, or heterocycle, wherein any ring atom is optionally independently substituted with halo, C 1-5 alkyl, nitro, cyano, trihalomethyl, C 1-5 alkoxy, C-amido, N-amido, sulfonamide, amino, aminosulfonyl, hydroxyl, mercapto, alkylthio, sulfonyl, sulfinyl, wherein C 1-5 alkyl, C 1-5 alkoxy, C-amido, N-amido, amino, and alkylthio are each optionally substituted with heteroaryl, heterocyclo, cycloalkyl, alkoxy, or amino;
o, p, and q are each independently 0, 1, or 2;
any alkylene or alkenylene group of the o, p, and q regions and of Y 2 is optionally substituted with unsubstituted C 1-4 alkyl, halo, unsubstituted C 1-4 haloalkyl, or unsubstituted C 3 or C 4 cycloalkyl;
with the proviso that when Y 1 is divalent phenyl, q is 0, and p is 1, then Y 4 is present;
with the proviso that when Y 1 is C 2-8 alkylene and q is 0, then Y 4 is present; and
with the proviso that the compound is NOT:
2-cyano-1-[[4-[(4-phenylphenyl)sulfonylamino]phenyl]methyl]-3-(4-pyridyl)guanidine.
51 - 202 . (canceled)
203 . The compound of claim 29 , wherein the compound is selected from a compound of Table 5 or Table 6.
204 . A pharmaceutical composition comprising a compound of claim 29 and a pharmaceutically acceptable excipient.
205 . A method of treating cancer, comprising administering a therapeutically effective amount of a compound of a pharmaceutical composition of claim 204 to a patient.
206 - 235 . (canceled)
236 . A method of inhibiting the activity of Nampt in human cells comprising, contacting said cells with a compound of claim 29 .
237 - 239 . (canceled)
240 . A method of making a compound of claim 29 , comprising: reacting
under suitable conditions to yield the intermediate
converting said intermediate to a second intermediate
reacting said second intermediate with Y—(CH 2 ) q —NH 2 to yield
wherein Y, Y 1 , o, p, and q, are as defined in claim 29 , and
wherein R 1 , R 3 , and R 4 are as defined in claim 39 .